Skip to content
Back to meeting Original
Peter Pattison· @bsc_io_e · X·· 1 day agoScore45
Body

Presented @ #ESMO26 | #ROWANStudy:
Adverse events were consistent with the known safety profiles of #TheraSphere #Y90 and durvalumab+tremelimumab (STRIDE) #immunotherapy, supporting continued evaluation of TheraSphere in combination with immunotherapy for #livercancer. #HCC
 
Learn more: https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/presentation/list?q=rowan

7 views · 0 likes · 0 reposts · 0 replies

Source: Peter Pattison · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.